1. Introduction {#sec1}
===============

Obesity is the main risk factor for type 2 diabetes (T2D) and is due to an imbalance between energy intake and energy expenditure. Current anti-obesity drugs affecting energy intake or intestinal lipid absorption cause important and troublesome side effects for the patient, which limits their use. On the other hand, bariatric surgery has proven efficient for obesity and for diabetes remission with a dramatic effect on insulin resistance, although long-term complications and obesity relapse may arise. Therefore, understanding the signaling pathways that control fat storage and energy expenditure may open alternative avenues against obesity and linked T2D.

In animal models, genes such as *E2f1* and *Sertad2* (TRIP-Br2) have been shown to prevent fat accumulation and protect against diet-induced obesity (DIO), but they also improve insulin action in metabolic organs including adipose tissue [@bib1], [@bib2], [@bib3]. Two major types of adipose tissues exist that are anatomically and functionally distinct: white (WAT) and brown (BAT) adipose tissues. Recent studies have revealed a new distinct type of thermogenic adipocyte intermingled within WAT, named beige cells (also known as brite cells). White adipocytes store excess energy as triacylglycerol and release free fatty acids (FFAs) as energy substrate when required. On the other hand, the catabolic capability of BAT and beige adipocytes to burn fat contributes to reduce circulating FFAs. Indeed, BAT expresses high levels of uncoupling protein 1 (UCP1), leading to substrate oxidation and subsequent heat production and energy expenditure (for review, see Ref. [@bib4]). Beige adipocytes also express UCP1 and develop under cold exposure. This adaptive process is called WAT beiging/browning [@bib5]. In pathological conditions such as obesity, elevated circulating FFAs are associated with insulin resistance and T2D. Since energy balance is modulated by food intake, physical activity, as well as non-shivering thermogenesis in BAT, increasing energy expenditure by classical BAT activation or by promoting browning of WAT have recently emerged as new putative therapy to alleviate the effects of obesity and prevent insulin resistance and T2D [@bib4], [@bib6]. Recent reports in humans further confirmed the important function of brown/beige adipocytes in enhancing glucose tolerance and insulin sensitivity [@bib7], [@bib8]. Therefore, the identification of selective molecular pathways for beige adipocyte biogenesis would represent a first step towards innovative therapeutic options.

Genome-wide association studies (GWASs) have established the *CDKN2A/B* locus as a hotspot influencing genetic risk for different cardio-metabolic diseases including T2D [@bib9], [@bib10]. *CDKN2A/B* single nucleotide polymorphisms associated with T2D also modulate fasting insulin and insulin sensitivity in non-diabetic subjects [@bib11]. In particular, rs10757278-G and rs10811661-T SNPs are situated near the *CDKN2A/B* locus on chromosome 9p21.3 and are respectively associated with the risk for coronary artery disease (CAD) and T2D [@bib12]. The genomic regions containing those SNPs are also in close vicinity of the long non-coding RNA *ANRIL* (Antisense Non-coding RNA in the Inhibitor of CDK4 (INK4) Locus). The function of *ANRIL* is still unknown but it seems to be involved in the epigenetic repression of the *CDKN2A/B* locus [@bib13]. Although rs10757278 and rs10811661 are less than 10 kb away from CDKN2A/B genes, those SNPs may affect dynamic chromosome structures and genome activity. Indeed, rs10811661 is negatively associated with a trans-eQTL, presenilin 1 (*PSEN1*), a gene associated in mice with glucose intolerance and insulin resistance [@bib14]. In addition, Lillycrop et al. recently demonstrated that decreased DNA methylation at the *CDKN2A* gene is associated with a higher risk for a child to develop obesity during adulthood [@bib15]. Furthermore, rare heterozygous loss-of-function mutations in *CDKN2A* affect glucose homeostasis through its metabolic role in pancreatic beta cells and liver [@bib16]. Altogether, those results pinpoint the importance of studying the impact of loss-of-function of *CDKN2A* in metabolic tissues.

The human *CDKN2A* locus encodes for p16^INK4a^ a CDK inhibitory (CDKI) protein and the p53 regulatory protein p14^ARF^ (p19^ARF^ in mice), whereas the *CDKN2B* gene encodes another CDKI, p15^INK4b^. Products of the *CDKN2A/B* locus are involved in apoptosis, senescence, and aging [@bib9]. Whilst p16 and p15 are potent CDKI preventing binding of CDK4/6 to Cyclin D, p14^ARF^ mainly exerts it anti-proliferative activity *via* the inhibition of MDM2, an ubiquitin-ligase that modulates the activity of the tumor suppressor p53. The CDKN2A/B pathway is involved in metabolic control through several ways including adipocyte differentiation [@bib17], [@bib18], [@bib19], macrophage polarization [@bib20], fasted--fed transition [@bib21], [@bib22], muscle metabolism [@bib1], and pancreatic beta cell proliferation, regeneration, and function [@bib23], [@bib24], [@bib25].

While rodent and human studies have highlighted the potential role of *CDKN2A* on insulin secretion [@bib16], [@bib26], the contribution of *CDKN2A* to the control of insulin sensitivity is still elusive.

To decipher the link between *Cdkn2a*, obesity and insulin resistance, we analyzed the effect of *Cdkn2a* deficiency in mice on metabolic homeostasis [@bib27]. Here, we demonstrate that the genetic deletion of *Cdkn2a* promotes energy expenditure and improves insulin sensitivity during DIO. We found that the *Cdkn2a* locus modulates signaling pathways in inguinal WAT (ingWAT), where it controls beige adipocyte development. Importantly, we observed that *CDKN2A* expression is increased in adipocytes from obese patients. *CDKN2A* silencing during human-induced pluripotent stem cells adipogenic differentiation promoted UCP1 expression. These data suggest that *Cdkn2a* plays a key role in energy metabolism by regulating a white-to-brown fat transition.

2. Material and methods {#sec2}
=======================

2.1. Materials and oligonucleotides {#sec2.1}
-----------------------------------

Chemicals, unless stated otherwise, were purchased from Sigma--Aldrich. Anti-UCP1 antibody was purchased from Abcam, and anti-PKA substrate antibody was from Cell Signaling Technology. The oligonucleotides sequences used for various experiments are listed in [Table S5](#appsec1){ref-type="sec"}.

2.2. Animals experiments {#sec2.2}
------------------------

*Cdkn2a+/+* and *Cdkn2a−/−* mice were previously described [@bib27] and were maintained on a mixed background according to European Union guidelines for use of laboratory animals. *In vivo* experiments were performed in compliance with the French ethical guidelines for studies on experimental animal (Animal house agreement no. B 59-35015, Authorization for Animal Experimentation no. 59-350294, project approval by our local ethical committee no. CEEA 482012). All experiments were performed with healthy male mice. Animals with detectable tumors were excluded from the study. Mice were housed under a 12 h light--dark cycle and given a regular chow (A04; Safe). For HFD studies, 8-week old mice were placed on D12492 diet (60% cal/fat; Research Diet Inc.) for 13 weeks. Metabolic phenotyping experiments were performed according to the EMPRESS protocols (<http://empress.har.mrc.ac.uk>). Briefly, intraperitoneal glucose (2 g of glucose per kg of body weight) and insulin (0.75 U of insulin per kg of body weight) tolerance tests were performed as previously described [@bib28], [@bib29] on 16-h-fasted animals for IPGTT and 5-h-fasted animals for ITT. Glycemia was measured before and at different time after glucose and insulin injections using the Accu-Check Performa (Roche Diagnostics). Circulating insulin levels were measured using the Ultrasensitive Insulin Elisa kit (Mercodia). For cold experiments, mice were maintained at +23 °C or placed at +4 °C for 5h and fasted during the time of the experiment. Body temperature was measured using a rectal probe as described previously [@bib1]. Metabolic rate was measured by indirect calorimetry using the Phenomaster metabolic cage system (TSE Systems). Mice were housed individually and maintained at 23 °C under a 12 h light/12 h dark cycle. Food and water were available *ad libitum*. Mice were sacrificed by cervical dislocation and tissues were harvested and snap-frozen for further processing.

2.3. RNA extraction, measurements, and profiling {#sec2.3}
------------------------------------------------

Total RNA was extracted from rodent cells and tissues using trizol reagent (Life Technologies) as described previously [@bib1], [@bib28]. mRNA expression was measured after reverse transcription by quantitative real-time PCR (qRT-PCR) with FastStart SYBR Green master mix (Roche) according to the manufacturer\'s recommendations and gene-specific oligonucleotides. Mouse qRT-PCR results were normalized to endogenous cyclophilin reference mRNA levels. The results are expressed as the relative mRNA level of a specific gene expression using the formula 2^−ΔCt^. For human cells, RNAs were purified on RNeasy Plus Universal columns (Qiagen, France) according to the manufacturer\'s instructions. Total RNA sample concentrations were determined using a Nanodrop spectrophotometer (Thermo Scientific, Waltham, MA, USA). 1 μg RNA was used for reverse transcription. Real-time PCR assays were run on a OneStep real-time PCR machine (Applied Life Sciences) and SYBR green was from Applied Biosystems. Normalization was performed using the geometric averages of the housekeeping gene *TBP*. Delta Ct values were used to achieve relative quantification of gene expression when "expression relative to *TBP*" is indicated.

2.4. Histology, immunofluorescence (IF), and immunohistochemistry (IHC) {#sec2.4}
-----------------------------------------------------------------------

IF and IHC were performed exactly as described previously [@bib1], [@bib28]. Briefly, deparaffinized adipose tissues sections (5 μm) were subjected to heat-induced antigen retrieval. The slides were incubated with 0.3% H~2~O~2~ for 10 min to quench the endogenous peroxidase. The sections were then incubated in 1% BSA/PBS for 10 min, followed by overnight incubation with primary (Rabbit-UCP1) antibodies at 4 °C. Afterward, the slides were incubated at room temperature for 2 h with horseradish peroxidase (HRP)-conjugated (for IHC) or Alexa-conjugated anti-rabbit secondary antibodies (for IF, Fischer Scientific). The IHC staining was developed using fast 3,3′-diaminobenzidine (DAB) tablet sets (D4293; Sigma, St. Louis, MO, USA). The sections were counterstained with hematoxylin and examined by light microscopy. H&E staining was performed using classical protocols. For IF, nuclei were stained with Hoechst. Images were processed using ImageJ software by two observers blinded to experimental groups.

2.5. Protein extracts, PKA activity measurement and immunoblot analysis {#sec2.5}
-----------------------------------------------------------------------

Immunoblot was performed as described previously [@bib1], [@bib29]. Tissues and cells were washed using cold PBS, and lysis was performed by using 50 mM Tris--HCl pH 8, 137 mM NaCl, 10% glycerol, 1% NP-40 and phosphatase, protease, deacetylase inhibitors (Sigma--Aldrich) on ice. Western blotting was performed using 30 μg of proteins loaded on SDS-PAGE precast gel (Biorad). After electrotransfer, the membrane was blocked for 1 h at room temperature with 5% nonfat milk in 0.1% Tween--Tris-buffered saline (TTBS) buffer. Membranes were then incubated overnight at 4 °C with primary antibodies as indicated in blocking buffer containing 5% nonfat milk or 0.5% bovine serum albumin at the dilution specified by the manufacturers. Subsequently, membranes were incubated with the secondary antibody conjugated with the horseradish peroxidase enzyme. The visualization of immunoreactive bands was performed using the enhanced chemiluminescence plus western blotting detection system (GE Healthcare). hiPSCs-BAP cells were rinsed with PBS and solubilized in stop buffer containing 50 mM Hepes, pH 7.2, 150 mM NaCl, 10 mM EDTA, 10 mM Na~4~P~2~O~7~, 2 mM Na~3~VO~4~, and 1% Triton X-100 supplemented with Protease Inhibitor Cocktail (Roche). The primary antibodies and dilutions used were: UCP1 (1/500, Abcam), Tubulin (1/10,000, Sigma); secondary horseradish peroxidase-conjugated antibodies were purchased from Sigma. Quantitation of protein signal intensity was performed by volume densitometry using the ImageJ 1.47t software (National Institutes of Health). PKA activity was measured on tissue homogenates using the non-radioactive PKA Kinase Activity assay kit following manufacturers\' instructions (Abcam).

2.6. Primary adipocyte cell culture {#sec2.6}
-----------------------------------

The stromal vascular fraction (SVF) of inguinal adipose or BAT tissues of 8-week old mice was isolated by collagenase (ROCHE) digestion followed by two alternative filtration steps (using 100 and 40 μM strainers) and centrifugations for 5 min at 700 × rpm. Cells were then plated and differentiated upon confluence in DMEM/F-12 GlutaMAX with adipogenic cocktail (0.5 mM 3-isobutyl-1-methylxanthine \[IBMX\], 2.5 μM dexamethasone, 1 μM rosiglitazone, 0.02 μM insulin for inguinal cells and 0.02 μM insulin, 0.125 μM indomethacin, 0.5 mM 3-isobutyl-1-methylxanthine \[IBMX\], 2.5 μM dexamethasone and 1 nM T3, for BAT cells) for 48 h. Inguinal cells were maintained in 0.02 μM insulin and BAT cells in 1 nM T3 and 0.02 μM insulin. Cells were harvested at days 8 post-differentiation. To label lipid droplets, fully differentiated primary adipocytes cells were fixed in 4% PFA then labeled with BODIPY 493/503 lipid probe solution (Molecular Probes/Life Technologies) for 30 min. After PBS wash the staining was examined by fluorescence microscopy.

2.7. Cell culture and siRNA experiments {#sec2.7}
---------------------------------------

Brown-like adipose progenitors (BAPs) were derived from human-induced pluripotent stem cells (hiPSCs) and induced to undergo adipocyte differentiation as described in Mohsen-Kanson et al. [@bib65] and Hafner et al. [@bib66]. For more details see <http://www.nature.com/protocolexchange/protocols/5175>. hiPSC-BAPs were transfected with small interfering RNA duplexes (Human CDKN2A siRNA-SMART pool, GEHealth Bio-Sciences, Rosersberg, Sweden) using HIPerfect reagent (Qiagen, France) during the exponential growth phase as described by the supplier.

2.8. Pamgene experiments {#sec2.8}
------------------------

For kinome analysis, STK microarrays were purchased from PamGene International BV (STK pamchips, Ref. [@bib32]). Each array contained 140 phosphorylatable peptides as well as 4 control peptides. Sample incubation, detection, and analysis were performed in a PamStation 12 according to the manufacturer\'s instructions. Briefly, extracts from fully differentiated day 8 (D8) primary adipocytes from *Cdkn2a+/+* and *Cdkn2a−/−* mice were freshly prepared using M-PER mammalian extraction buffer (Thermo Scientific) containing 1:50 Halt phosphatase inhibitor cocktail (Thermo Scientific) and 1:50 Halt protease inhibitor cocktail, EDTA-free (Thermo Scientific) for 20 min on ice. The lysates were then centrifuged at 15,871 g for 20 min to remove all debris. The supernatant was aliquoted, snap-frozen in liquid nitrogen, and stored at −80 °C until further processing. Prior to incubation with the kinase reaction mix, the arrays were blocked with 2% BSA in water for 30 cycles and washed 3 times with the PK assay buffer. Kinase reactions were performed for 1 h with 2.5 μg of total extract of the mature adipocyte and 400 μM ATP at 30 °C. Phosphorylated peptides were detected with an anti-rabbit-FITC antibody that recognizes a pool of anti-phospho serine/threonine antibodies. The instrument contains a 12-bit CCD camera suitable for imaging of FITC-labeled arrays. The images obtained from the phosphorylated arrays were quantified using the BioNavigator software (PamGene International BV), and the list of peptides whose phosphorylation was significantly different between *Cdkn2a+/+* and *Cdkn2a−/−* was uploaded to IPA for pathway analysis. The BioNavigator software was used to perform the HPRD based upstream kinase determination that is shown in [Figure 4](#fig4){ref-type="fig"}C.

2.9. RNA sequencing {#sec2.9}
-------------------

Total RNA was extracted from primary adipocytes 8 days after differentiation using the RNeasy Microkit (Qiagen) following manufacturer\'s instructions. RNA quality was verified using RNA 6000 nanochips on the Agilent 2100 bioanalyzer. Purified RNA (200 ng) with RNA integrity number ≥8 was subsequently used for library preparation (TruSeq Stranded mRNA Library Preparation Kit, Illumina) and sequenced on a HiSeq2500 (Illumina). Three biological replicates per condition were sequenced in paired-end. A mean of 54 million paired-end reads of 75 bp were generated for each sample. After initial checks and validation of sequence quality, RNA-seq reads were aligned to the mouse reference genomes (mm10) using TopHat2 [@bib33]. Subsequently, both quantification and annotation of the reads were performed using Bioconductor package Rsubread [@bib34]. Finally, the differential gene expression analyses were performed using Bioconductor package DESeq2 [@bib35]. Using a *p* \< 0.05 adjusted for multiple comparisons as threshold, we then performed pathway analysis using Ingenuity Pathway Analysis (Ingenuity Sytems).

2.10. Seahorse experiments {#sec2.10}
--------------------------

Oxygen consumption rate (OCR) was performed using the XF24e platform from Seahorse Biosciences. Primary adipocytes from *Cdkn2a+/+* and *Cdkn2a−/−* mice were grown and differentiated in a Seahorse plate. Growth medium was replaced with 37 °C seahorse DMEM 1 h before the measurement to allow equilibrium. Measurement was performed at 37 °C, using 3--3--3-min intervals. Basal respiration was measured then uncoupled, and maximal OCR were determined using oligomycin and carbonyl cyanide p-trifluoromethoxyphenylhydrazone (FCCP, 1 μM each), respectively. Complex I-dependent respiration was inhibited with rotenone (3 μM). OCR data were normalized using total protein or DNA content as indicated.

2.11. Human adipocyte expression data {#sec2.11}
-------------------------------------

Gene Expression Omnibus (GEO) analysis from the NCBI was performed using "adipocytes obese human" as keywords, filtered with "published in the last year" and sorted by the number of samples "high to low". The dataset [GSE94753](ncbi-geo:GSE94753){#intref0020} [@bib36] was selected and analyzed using GEO2R. The platform [GPL11532](ncbi-geo:GPL11532){#intref0025} was selected and groups were defined using the disease status (lean, WAT, control *versus* obese resistant, WAT OIR). Expression level data were extracted from "profile graph" using *CDKN2A* ID 8160441.

2.12. Statistical analysis {#sec2.12}
--------------------------

Data are presented as mean ± SEM. Statistical analyses were performed using unpaired two-tailed Student\'s *t*-test, one-way ANOVA with least significant difference Bonferroni post hoc test or two-way ANOVA with Bonferroni post hoc tests as appropriate using GraphPad Prism software. Differences were considered statistically significant at *p* \< 0.05 (\**p* \< 0.05; \*\**p* \< 0.01 and \*\*\**p* \< 0.001).

3. Results {#sec3}
==========

3.1. Germline *Cdkn2a* deficiency improves insulin sensitivity in mice {#sec3.1}
----------------------------------------------------------------------

We first analyzed the metabolic profile of *Cdkn2a*-deficient mice [@bib27]. 9- to 12-week old *Cdkn2a+/+* and *Cdkn2a−/−* mice fed a chow diet (CD) displayed similar body weight ([Figure 1](#fig1){ref-type="fig"}A), glucose tolerance ([Figure 1](#fig1){ref-type="fig"}B, C) and fasting glycemia ([Figure S1](#appsec2){ref-type="sec"}A). *In vivo* glucose stimulated insulin secretion (GSIS) was similar in both genotypes under CD ([Figure 1](#fig1){ref-type="fig"}D). After 13 weeks of high fat diet (HFD) feeding, body weight of *Cdkn2a−/−* mice was lower than that of age-matched control mice ([Figure 1](#fig1){ref-type="fig"}E), with comparable fasting glucose levels ([Figure S1](#appsec2){ref-type="sec"}B) and similar glucose clearance during ipGTT tests ([Figure 1](#fig1){ref-type="fig"}F, G). As expected, upon HFD feeding *Cdkn2a+/+* had increased basal insulin secretion to maintain normal glucose levels, indicating an insulin-resistant state ([Figure 1](#fig1){ref-type="fig"}H). By contrast, HFD *Cdkn2a*-deficient mice displayed lower basal insulin levels and were still responsive to a glucose load ([Figure 1](#fig1){ref-type="fig"}H), suggesting that *Cdkn2a* deficiency may affect insulin sensitivity rather than insulin production by the pancreatic beta cells. Consistently, insulin sensitivity was significantly improved in *Cdkn2a−/−* mice under CD ([Figure 1](#fig1){ref-type="fig"}I, J) and even more under HFD ([Figure 1](#fig1){ref-type="fig"}K, L). These results indicate that *Cdkn2a* deficiency prevents weight gain and improves insulin sensitivity during metabolic stress.Figure 1***Cdkn2a*-deficient mice are insulin sensitive during DIO.** (A) Body weight of 9- to 12-week old control (*Cdkn2a+/+*) and mutant (*Cdkn2a−/−*) mice fed with chow diet (CD, *n* = 30--32). (B, C) Intraperitoneal glucose tolerance test (ipGTT, B) in *Cdkn2a+/+* and *Cdkn2a−/−* mice fed with CD (*n* = 11--12) and the corresponding area under the curve (AUC, C) of ipGTT. (D) Blood insulin levels as measured during ipGTT in CD-fed mice. (E) Body weight of high fat diet (HFD, *n* = 7--16) fed mice. (F, G) ipGTT in HFD mice (F, *n* = 7) and its AUC (G). (H) Blood insulin levels during ipGTT in HFD-fed mice. (I) Intraperitoneal insulin tolerance test (ipITT) in 8 weeks mice fed with CD (*n* = 7). (J) AUC of ipITT. (K, L) ipITT in HFD-fed mice (K, *n* = 7) and the corresponding AUC of ipITT (L). All values are expressed as means ± SEM; \**p* \< 0.05, \*\**p* \< 0.01, and \*\*\**p* \< 0.001.

3.2. Increased energy expenditure in *Cdkn2a−/−* mice {#sec3.2}
-----------------------------------------------------

To characterize the effect of *Cdkn2a* deficiency on insulin sensitivity and body weight, we monitored energy expenditure using indirect calorimetry measurements. Under CD, *Cdkn2a−/−* mice showed increased food intake only during the second (1AM to 7AM) part of the dark phase compared to controls ([Figure 2](#fig2){ref-type="fig"}A and [Figure S2](#appsec2){ref-type="sec"}A), but this was doubled under HFD during the entire dark phase ([Figure 2](#fig2){ref-type="fig"}B and [Figure S2](#appsec2){ref-type="sec"}B). The reduced body weight gain under HFD ([Figure 1](#fig1){ref-type="fig"}) despite an increase in food intake suggests enhanced energy expenditure. The ambulatory activity was similar among all genotypes either under CD ([Figure S2](#appsec2){ref-type="sec"}C, D) or HFD ([Figure S2](#appsec2){ref-type="sec"}E, F). Interestingly, *Cdkn2a−/−* mice showed increased energy expenditure measured by heat production, under both CD ([Figure 2](#fig2){ref-type="fig"}C and [Figure S2](#appsec2){ref-type="sec"}G) and HFD ([Figure 2](#fig2){ref-type="fig"}D and [Figure S2](#appsec2){ref-type="sec"}H). This increased metabolic rate was not due to substrate utilization preference (glucose or free fatty acids), since no significant difference in respiratory exchange ratio (RER) was observed between *Cdkn2a+/+* and *Cdkn2a−/−* mice ([Figure 2](#fig2){ref-type="fig"}E, F and [Figure S2](#appsec2){ref-type="sec"}I, J). We then investigated adaptive thermogenesis by either performing a cold test or subjecting mice to 6 h of fasting. During an acute cold stress or under fasting conditions *Cdkn2a−/−* mice maintained a higher body temperature as compared to control animals ([Figure 2](#fig2){ref-type="fig"}G, H). Altogether, these findings suggest that the global genetic deletion of *Cdkn2a* locus in mice enhances energy expenditure and adaptive thermogenesis.Figure 2**Increased energy expenditure in *Cdkn2a−/−* mice.** (A, B) Cumulative food intake in (A) CD and (B) HFD-fed control (*Cdkn2a+/+*) and mutant (*Cdkn2a*−/−) mice (*n* = 4) measured during the dark (7PM to 1AM and 1AM to 7AM) and the light (7AM to 1PM and 1PM to 7PM) periods. (C, D) Heat production in (C) chow diet and (D) HFD-fed mice. (E, F) Respiratory exchange ratio (RER) in (E) CD and (F) HFD-fed mice. (G, H) Body temperature in CD-fed *Cdkn2a+/+* and *Cdkn2a−/−* mice after 5 h fasting (G, *n* = 4) and 5 h of cold exposure (H, *n* = 4). All values are expressed as means ± SEM; \**p* \< 0.05, \*\**p* \< 0.01, and \*\*\**p* \< 0.001.

3.3. Beige fat programming is dependent on *Cdkn2a* {#sec3.3}
---------------------------------------------------

To determine if *Cdkn2a* regulates brown and beige adipocyte function, we first analyzed BAT thermogenic gene expression in *Cdkn2a+/+* and *Cdkn2a−/−* mice. *Ucp1* and *Prdm16* expression increased in *Cdkn2a*-deficient BAT fed a CD or HFD ([Figure 3](#fig3){ref-type="fig"}A, B). *Ppargc1a* expression was similar in control and *Cdkn2a*-deficient BAT under CD, but raised upon HFD in *Cdkn2a−/−* BAT ([Figure 3](#fig3){ref-type="fig"}A, B). Mitochondrial content ([Figure S3](#appsec2){ref-type="sec"}A) and Ucp1 protein levels ([Figure S3](#appsec2){ref-type="sec"}B, C) were identical in *Cdkn2a+/+* and *Cdkn2a−/−* BAT tissue homogenates. Total BAT mass was not significantly different in *Cdkn2a+/+* and *Cdkn2a−/−* mice fed CD, but was decreased in HFD-fed *Cdkn2a−/−* mice ([Figure S3](#appsec2){ref-type="sec"}D, E). When expressed relative to total body weight no difference between genotypes was observed ([Figure S3](#appsec2){ref-type="sec"}F, G), suggesting that *Cdkn2a* deficiency may have a week effect on BAT functions. When measuring *p16*, *p19*, and *Ucp1* mRNA levels in different mouse fat depots, we observed that p16 ([Figure 3](#fig3){ref-type="fig"}C) and p19 ([Figure 3](#fig3){ref-type="fig"}D) were mostly expressed in inguinal WAT (ingWAT) compared to epididymal WAT or BAT, whereas *Ucp1* ([Figure 3](#fig3){ref-type="fig"}D) was strongly expressed in BAT depots. We then hypothesized that the *Cdkn2a* gene products *p16* and *p19* may promote the WAT beiging/browning process. To determine if *Cdkn2a* deficiency modifies beige adipocyte differentiation, we compared the expression levels of several adipocyte markers between control and *Cdkn2a*-deficient animal\'s ingWAT. The expression of brown fat-selective genes *Ppargc1a*, *Ucp1*, *Prdm16*, *Tfam*, *Cox5a*, *Cox8a*, and *Dio2* was increased in ingWAT from CD-fed *Cdkn2a−/−* animals ([Figure 3](#fig3){ref-type="fig"}F). This effect was more pronounced in HFD-*Cdkn2a−/−* ingWAT ([Figure 3](#fig3){ref-type="fig"}G). Hematoxylin and eosin (H&E) staining showed that *Cdkn2a−/−* ingWAT had smaller adipocytes with multilocular lipid droplets ([Figure 3](#fig3){ref-type="fig"}H), associated with an increase in UCP1 immunostaining ([Figure 3](#fig3){ref-type="fig"}H), further confirmed through immunoblot ([Figure 3](#fig3){ref-type="fig"}I, J) and immunofluorescence ([Figure S3](#appsec2){ref-type="sec"}H) experiments. Mitochondrial content was identical in *Cdkn2a+/+* and *Cdkn2a−/−* ingWAT ([Figure S3](#appsec2){ref-type="sec"}A). Altogether, these data suggest that *Cdkn2a* deficiency induces a white-to-brown fat conversion in ingWAT.Figure 3***Cdkn2a* deficiency promotes the browning process *in vivo*.** (A, B) mRNA level of thermogenic genes in BAT from *Cdkn2a+/+* and *Cdkn2a−/−* mice fed chow (A) or HFD (B, *n* = 5--6). (C--E) mRNA levels of *p16* (C), *p19* (D) and *Ucp1* (E) in epididymal WAT (epiWAT), inguinal WAT (ingWAT) and BAT. (F, G) mRNA levels for adipogenic and thermogenic genes in ingWAT from *Cdkn2a+/+* and *Cdkn2a−/−* mice fed CD (F) or HFD (G, *n* = 5--6). An inset of some genes is represented. (H) Hematoxylin and eosin (H&E) staining and UCP1 immunohistochemistry of representative sections of ingWAT from *Cdkn2a+/+* and *Cdkn2a−/−* mice fed CD. (I, J) Western blot assay (I) and quantification (J) showing UCP1 protein levels in ingWAT of *Cdkn2a+/+* and *Cdkn2a−/−* mice. Tubulin was used as a loading control. Quantification was performed using the ImageJ software. All values are expressed as means ± SEM; \**p* \< 0.05, \*\**p* \< 0.01, and \*\*\**p* \< 0.001.

3.4. The effect of *Cdkn2a* on browning is cell-autonomous and requires the activation of the Protein Kinase A pathway {#sec3.4}
----------------------------------------------------------------------------------------------------------------------

Stromal vascular cells from ingWAT and BAT can be differentiated into brown-like adipocytes. To determine the cell-autonomous requirement of *Cdkn2a* to the beiging process, we isolated ingWAT and BAT pre-adipocytes from control and *Cdkn2a*-deficient mice and differentiated them for 8 days ([Figure S4](#appsec2){ref-type="sec"}A). Lipid droplet accumulation was more pronounced in *Cdkn2a−/−* ingWAT and BAT differentiated primary adipocytes, but not in adipocytes differentiated from epididymal pre-adipocytes (eWAT, [Figure S4](#appsec2){ref-type="sec"}B). We next examined the expression of adipocytes (*Fabp4*) and brown/beige fat markers (*Ppargc1a*, *Ucp1*, *Prdm16*, *Cox5a*, *Cidea*, *Elovl3*, *Dio2*) and observed a strong induction of these genes in differentiated ingWAT primary cells upon *p16* and *p19* genetic deletion ([Figure 4](#fig4){ref-type="fig"}A), but not in differentiated BAT or eWAT primary cells ([Figure S4](#appsec2){ref-type="sec"}C and data not shown).Figure 4**Activation of the Protein Kinase A pathway in *Cdkn2a−/−* adipocytes induces white adipose tissue browning.** (A) mRNA levels for adipogenic and thermogenic genes in ingWAT primary differentiated adipocytes isolated from *Cdkn2a+/+* and C*dkn2a−/−* mice (*n* = 3). (B) Heatmap showing differences in peptide phosphorylation between primary differentiated adipocyte from *Cdkn2a+/+* and *Cdkn2a−/−* inguinal fat depots (*n* = 3). Upstream kinases were identified using the Human Protein Reference Database. (C) Pamgene results were analyzed using Ingenuity Pathway Analysis (IPA) to identify the top activated canonical pathways in *Cdkn2a−/−* primary differentiated adipocyte compared to *Cdkn2a+/+*. (D) PKA activity measurement in tissue homogenates from BAT and ingWAT isolated from *Cdkn2a+/+* and *Cdkn2a−/−* mice (*n* = 3) treated with DMSO or the PKA inhibitor H89 at 10 μM. (E, F) Oxygen consumption rate (OCR) was measured using the Seahorse XFe24 platform. After 8 days of differentiation (D8), OCR was measured in *Cdkn2a+/+* and *Cdkn2a−/−* differentiated adipocytes (E) and quantification of basal respiration, basal proton leak (by blocking ATP synthase activity with oligomycin), maximal respiration by stimulating uncoupling process with FCCP (carbonyl cyanide p-trifluoromethoxyphenylhydrazone) and non-mitochondrial respiration (with rotenone) is represented (F, *n* = 5). *Cdkn2a−/−* cells were treated 1 h with 10 μM of PKA inhibitor H89 before the experiment (*n* = 5). All values are expressed as means ± SEM; \**p* \< 0.05, \*\**p* \< 0.01, and \*\*\**p* \< 0.001.

The *Cdkn2a* products p16^ink4a^ and p19^ARF^ are key regulators of the activity of serine/threonine kinases (STK) involved in cell proliferation and senescence [@bib9]. We postulated that STK may be involved in beige fat programming and performed a global kinome analysis in primary *Cdkn2a+/+* and *Cdkn2a−/−* differentiated adipocytes. We used Pamgene arrays containing 140 serine/threonine peptides that are the substrates of one or multiple kinases. We incubated these chips with protein lysates of primary adipocytes after 8 days of differentiation (D8). We then analyzed the phosphorylation status of these peptides and identified the putative upstream kinases involved. At D8, 47 peptides with significant differences in phosphorylation levels between control and *Cdkn2a*-deficient adipocytes were observed ([Figure 4](#fig4){ref-type="fig"}B and [Table S1](#appsec2){ref-type="sec"}). Using the Human Protein Reference Database (HPRD) [@bib37] to identify potential upstream kinases we identified several signaling pathways that may be affected in *Cdkn2a*-deficient adipocytes, including Protein Kinase A (PKA) and Protein Kinase G (PKG) signaling pathways. Interestingly, PKG is an important regulator of WAT browning [@bib38], [@bib39]. For some phosphorylated peptides upstream kinases could not be identified using HPRD analysis ([Figure 4](#fig4){ref-type="fig"}B, NA or --). When we analyzed the diseases and/or biological functions affected by the differences in peptide phosphorylation observed upon *Cdkn2a* genetic deficiency through Ingenuity Pathway Analysis (IPA), we found networks related to "Cancer," "Organismal Injury and Abnormalities," and "Developmental Disorders," but also to "Cardiovascular Disease" ([Table S2](#appsec2){ref-type="sec"}). Then we found a significant enrichment of potential signaling pathways upstream kinases involved in "Protein Kinase A Signaling" in *Cdkn2a*-deficient cells (*P* = 1.07 × 10^−15^; [Figure 4](#fig4){ref-type="fig"}C), confirming HPRD analysis. In addition, "AMPK signaling" (*P* = 4.96 × 10^−12^; [Figure 4](#fig4){ref-type="fig"}C), "synaptic long-term potentiation" (*P* = 1.28 × 10^−10^; [Figure 4](#fig4){ref-type="fig"}C), "prostate cancer signaling" (*P* = 9.26 × 10^−10^; [Figure 4](#fig4){ref-type="fig"}C) or "Molecular Mechanisms of Cancer" (*P* = 3.92 × 10^−09^; [Figure 4](#fig4){ref-type="fig"}C) were canonical pathways also affected in *Cdkn2a−/−* primary adipocytes. These analyses prompted us to focus on dissecting the contribution of PKA to our phenotype. Increased PKA activity was confirmed in *Cdkn2a−/−* ingWAT homogenates, whereas no changes were found in BAT or eWAT ([Figure 4](#fig4){ref-type="fig"}D and data not shown). The increased PKA activity was further confirmed in *Cdkn2a−/−* ingWAT using protein homogenates and an anti-PKA phospho-substrate antibody ([Figure S4](#appsec2){ref-type="sec"}D, E). The increase in PKA activity was associated with a significant raise in basal and maximal respiration, as well as basal proton leak of *Cdkn2a−/−* primary ingWAT cells, as measured by oxygen consumption rate (OCR, [Figure 4](#fig4){ref-type="fig"}E, F). The PKA inhibitor H89 completely abolished PKA activity in tissue homogenates ([Figure 4](#fig4){ref-type="fig"}D) as well as the increase of oxygen consumption observed in *Cdkn2a−/−* primary cells ([Figure 4](#fig4){ref-type="fig"}E, F). Altogether, these findings indicate that *Cdkn2a* modulates PKA activity in adipocytes, oxygen consumption and promotes beiging in ingWAT. Our results also suggest that *Cdkn2a* may regulate other pathways, such as PKG, that can further contribute to adipose beiging.

3.5. *Cdkn2a* modulates a regulatory gene network involved in brown adipocyte function {#sec3.5}
--------------------------------------------------------------------------------------

We next carried out RNA-sequencing (RNA-seq) analysis in *Cdkn2a+/+* and *Cdkn2a−/−* primary adipocytes at D8 of differentiation. We found 11,855 transcripts differentially expressed ([Table S3](#appsec2){ref-type="sec"}). IPA highlighted the presence of a network of 98 genes associated to *Cdkn2a* deletion which was involved in "energy production, lipid metabolism and small molecule biochemistry," including *Ppargc1a* and *Prdm16* ([Figure S5](#appsec2){ref-type="sec"}A). Subsequently, we analyzed the diseases and/or functions associated to *Cdkn2a* deficiency. The main differences between *Cdkn2a+/+* and *Cdkn2a−/−* primary adipocytes were included into "carbohydrate metabolism" (*P* = 1.67 × 10^−3^) or "cellular development, connective tissue development and function, tissues development" (*P* = 4.36 × 10^−3^; [Table S4](#appsec2){ref-type="sec"}). Next, we used the "upstream regulator analysis" function of IPA to identify potential contributors to the phenotype of *Cdkn2a+/+* and *Cdkn2a*−/− primary adipocytes. Among the most significant upstream regulators, tumor necrosis factor (TNF) and promyelocytic leukemia (PML) signaling pathways were activated ([Table 1](#tbl1){ref-type="table"}). Interestingly, norepinephrine, which acts on β-AR receptors in BAT [@bib40] and WAT [@bib41], [@bib42], was also activated ([Table 1](#tbl1){ref-type="table"}). This analysis further revealed a potential inhibition of the NR1H2 pathway, which has been associated to severe obesity [@bib43] ([Table 1](#tbl1){ref-type="table"}). Transcription factor network analyses revealed that PPARGC1A and PRDM16 were activated in *Cdkn2a−/−* cells ([Table 2](#tbl2){ref-type="table"}). The period circadian clock 2 (PER2) transcription factor was also activated ([Table 2](#tbl2){ref-type="table"}). This is consistent with the observation that PER2 is necessary for adaptation to cold temperature in mice through the regulation of *Ucp1* expression [@bib44]. Moreover, Aryl hydrocarbon receptor nuclear translocator like (ARNTL) activity is potentially inhibited in our model ([Table 2](#tbl2){ref-type="table"}), in agreement with its antagonistic role on PER2 in the control of the circadian rhythm. Finally, the marked inhibition of inhibitor of DNA (ID1) further confirmed the brown-like features of *Cdkn2a−/−* primary adipocytes. Indeed, germline deficient *Id1* mice are protected against DIO through enhanced energy expenditure [@bib45]. These RNA-seq data further suggest that *Cdkn2a* is a crucial regulator of effectors controlling the expression of brown-like markers.Table 1Pathway analysis of RNA-sequencing data in *Cdkn2a+/+* and *Cdkn2a−/−* primary adipocytes.Upstream regulatorExp log ratioMolecule typePredicted activation stateActivation *z*-score*p*-Value of overlapTarget molecules in datasetCIDECOther0.7866.82E−03ACADL,COX4I2,CYCS,DGAT2,EBF2,FOXC2,PNPLA2,PPARG,PPARGC1A,PPARGC1BCCDC3Other9.86E−03ACACA,DGAT2,FASNPPARGC1B−1.230Transcription regulator9.86E−03EGLN3,ERO1A,VEGFAMelatoninChemical -- endogenous mammalian9.86E−03ACACA,FASN,IRS1ARNTL−0.518Transcription regulator2.18E−02DBP,ELOVL6,PER2,PER3PTPN1Phosphatase−1.3872.62E−02IRS1,IRS2,PPARGC1A,PRDM16,TMEM26SGCB0.379Other3.31E−02DAG1,SGCD,SGCESGCD1.385Other3.31E−02DAG1,SGCB,SGCEIL1BCytokine3.31E−02IRS1,SERPINE1,VEGFAPNPLA2−0.896Enzyme−1.1314.23E−02ACADL,FASN,Gk,PPARGFFAR4G-protein coupled receptor4.60E−02INSR,IRS1TNFRSF1B0.504Transmembrane receptor4.60E−02SERPINE1,SOCS3STAT1Transcription regulator4.60E−02PPARG,SOCS3EGR1Transcription regulator4.60E−02CSF1,F3TGFB1Growth factor4.60E−02F3,SERPINE1TNFRSF1ATransmembrane receptor4.60E−02SERPINE1,SOCS3NorepinephrineChemical -- endogenous mammalian1.9302.03E−01ELOVL6,PPARGC1A,RBP4,SLC2A1,VEGFATNFCytokineActivated2.0482.27E−01AOC3,APLN,Celf1,DBI,F3,FABP5,FASN,FOS,INSR,NRIP1,PPARG,RELA,SERPINE1,SOCS3,TALDO1NR1H20.471Ligand-dependent nuclear receptorInhibited−2.4492.42E−01ELOVL6,FASN,PNPLA2,PRDM16,RB1,Saa3,SLC16A2PMLTranscription regulatorActivated2.0003.52E−01ACACA,ACOX1,FASN,PPARGC1ATable 2Analysis of upstream transcription factors in RNA-sequencing data from *Cdkn2a+/+* and *Cdkn2a−/−* primary adipocytes.Molecules in networkScoreFocus moleculesTop diseases and functionsCEBPA,FOXC2,ID1,KLF11,MDM2,PPARGC1A,PPARGC1B,PRDM16,RB1,SREBF1,STAT6,TP5339Cellular Development, Connective Tissue Development and Function, Tissue DevelopmentARNTL,DBP,PER223Behavior, Nervous System Development and Function, Organ MorphologyID3,TCF301Hematological System Development and Function, Lymphoid Tissue Structure and Development, Tissue MorphologyHDAC3,RELA01Cell Death and Survival, Neurological Disease, Organismal Injury and Abnormalities

3.6. *CDKN2A* modulates adipose tissue browning in human adipocytes {#sec3.6}
-------------------------------------------------------------------

We next questioned whether deregulated expression of *CDKN2A* could be associated to obesity in humans. Interestingly, using global transcriptome profiling of adipocytes from lean and obese subjects (GEO: [GSE94752](ncbi-geo:GSE94752){#intref0030}; Ref. [@bib36]) we observed a significant increase of *CDKN2A* mRNA expression levels in obese insulin-resistant adipocytes compared to lean controls ([Figure 5](#fig5){ref-type="fig"}A). We next wondered whether decreasing *CDKN2A* levels in human adipocytes could recapitulate some of the effects we observed in mice and induce browning in human cells. Recent reports demonstrated that human-induced pluripotent stem cells (hiPSCs) could be differentiated into brown/brite adipose progenitors (hiPSCs-BAP, Refs. [@bib30], [@bib31]). To further analyze whether *CDKN2A* modulates UCP1 expression in human cells, we silenced *CDKN2A* expression during the exponential growth phase of hiPSCs and differentiated them into brown/brite adipose cells during 22 days as described previously [@bib30], [@bib31]. As shown in [Figure 5](#fig5){ref-type="fig"}B, C, *p16* and *p14* mRNA levels were significantly reduced after silencing of the *CDKN2A* gene. In addition, *UCP1* mRNA levels were strongly induced in hiPSCs-BAP upon *CDKN2A* silencing ([Figure 5](#fig5){ref-type="fig"}D). This transcriptional effect was associated with a strong increase of UCP1 protein levels in hiPSCs-BAP *CDKN2A*-deficient cells ([Figure 5](#fig5){ref-type="fig"}E, F). Moreover, silencing *CDKN2A* increased lipid droplet accumulation and adipocyte differentiation in hiPSCs-BAP cells ([Figure 5](#fig5){ref-type="fig"}G). Altogether, our data indicate that *CDKN2A* is an important mediator of human adipose tissue browning.Figure 5***CDKN2A* is increased in obese insulin-resistant adipocytes and its silencing in hiPSCs-BAP cells induces UCP1 expression.** (A) Correlation between CDKN2A and human obesity. *CDKN2A* expression is upregulated in adipocytes from obese insulin-resistant patients. Analyses are based on the human dataset GEO: [GSE94752](ncbi-geo:GSE94752){#intref0045}. (B--D) Relative expression of *p16* (B), *p14* (C), and *UCP1* (D) genes in control (siCont) or *CDKN2A* silenced (si*CDKN2A*) hiPSCs-BAPs (*n* = 3). (E, F) Western blot assay (E) and quantification (F) showing UCP1 protein levels in control (siCont) or *CDKN2A* silenced (si*CDKN2A*) hiPSCs-BAPs (*n* = 3). Tubulin was used as a loading control. Quantification was performed using the ImageJ software. (G) Representative microscopy analysis of siCont and si*CDKN2A* hiPSCs-BAPs after differentiation showing increased lipid droplets upon *CDKN2A* silencing. All values are expressed as means ± SEM; \**p* \< 0.05 and \*\**p* \< 0.01.

4. Discussion {#sec4}
=============

Our results demonstrate that *CDKN2A* gene products p16^INK4A^ and p19^ARF^ are, beside their known role as cell cycle regulatory proteins, crucial regulators of adipocyte function and adaptation to metabolic stress. Previous studies have linked the *CDKN2A* locus to diabetes pathophysiology through its putative role on pancreatic islet biology [@bib16], [@bib25]. Here, we show that *CDKN2A*-loss may also impact energy balance and metabolic homeostasis *via* non-pancreatic dependent mechanisms. First, we observed that *CDKN2A* expression is increased in human obese adipocytes, and deletion of both p16^INK4a^ and p19^ARF^ protect mice from diet-induced obesity and associated insulin resistance by enhancing energy expenditure. Second, *Cdkn2a* invalidation enhances ingWAT plasticity, facilitating the acquisition of beige adipocytes phenotype. Increasing energy expenditure is associated with decreased blood glucose and triglycerides and improving hyperglycemia and dyslipidemia in both mice and humans [@bib8], [@bib46]. In humans, BAT activation by cold exposure positively affects body weight and insulin sensitivity [@bib7], [@bib47], [@bib48], [@bib49]. In addition, the implantation of human beige adipocytes in mice improves metabolic homeostasis [@bib50]. Interestingly, besides its classical BAT feature, human adult BAT also has some beige-like characteristics [@bib5], [@bib51], [@bib52]. Altogether these data suggest that beige adipocyte activation may be useful against obesity and related metabolic disorders. In this broad context, our data show that *CDKN2A* locus is involved in adipose tissue adaptation to metabolic challenges in mice and humans that may have potential implications for human obesity.

Although it is not yet clear whether short-term cold acclimation induces browning in humans [@bib7], severe adrenergic stress does activate human WAT browning [@bib53], [@bib54]. In mice, beige adipocytes appear after cold exposure or other inducers [@bib4]. In our model, we observed the presence of beige adipocytes in *Cdkn2a* invalidated mice in the absence of any browning inducing agent, suggesting that this locus may act as modulator of the β3-adrenergic receptor (β-AR) that controls the browning process. The link between β-AR signaling pathway, CDKN2A and the browning process remains yet to be elucidated.

Using a multiplex method for global kinase activity profiling in ingWAT, we identified the PKA pathway among the most significantly affected pathway in *Cdkn2a−/−* adipocytes. Furthermore we demonstrated that loss of *p16*^*INK4a*^ and *p19*^*ARF*^ expression is sufficient to activate the thermogenic program in ingWAT. We also confirmed that PKA activity was higher in *Cdkn2a*-deficient ingWAT, suggesting an *in vivo* activation of this pathway. Interestingly in the liver, p16^INK4A^ controls gluconeogenesis and PKA activation in a CDK4-dependent manner [@bib22]. In contrast in ingWAT, our kinome analysis revealed that CDK4 kinase activity, which is regulated by p16^INK4A^, is not modulated in the absence of *Cdkn2a*. Therefore, the effect on PKA signaling in ingWAT may be independent of the activation of CDK4. In agreement with this, the analysis of adipose tissues depots from mice expressing a constitutively active CDK4 form (CDK4^R24C^, Ref. [@bib55]) did not show any signs of browning (data not shown). Moreover, PKA activity is increased in epididymal WAT from *Cdk4*-deficient mice [@bib56]. Although we cannot rule out that other key signaling pathways, including PKG, could contribute to the phenotype observed in *Cdkn2a-*deficient mice, our observations suggest that the molecular mechanisms controlled by p16^INK4A^ and p19^ARF^ may be tissue-specific and independent of the *bona fide* cell cycle regulation, as previously described in the liver for other cell cycle regulators [@bib21]. As demonstrated for p16^INK4A^/CDK4 and p19^ARF^/mdm2 in the control of cell proliferation or senescence, respectively, it is tempting to speculate that p16^INK4A^ and p19^ARF^ may act as direct repressors of the PKA complex to regulate its activity. The potential interaction of these proteins with different yet specific partners may subsequently dictate metabolic *versus* proliferative functions of p16^INK4A^ and p19^ARF^.

It is noteworthy that *CDKN2A* loss-of-function is involved in cancer development, particularly melanoma [@bib57]. Recent reports shed light on the contribution of adipose tissue browning process in cancer-associated cachexia in rodents and humans [@bib58], [@bib59], [@bib60], [@bib61], [@bib62]. Here we describe a novel metabolic function for this key tumor suppressor gene in energy expenditure and adipose tissue browning. The activation of the β3-AR pathway during cachexia [@bib63], [@bib64], and the putative tight relationship between CDKN2A and β3-AR, further suggests that *CDKN2A* deficiency in cancer cells may profoundly affect energy homeostasis facilitating the development of cachexia.

In conclusion, our results demonstrate that the *Cdkn2a* locus is an important regulator of energy homeostasis and adipose tissue function in response to metabolic stress in mice. Mice model approaches can be useful to elucidate and further carefully dissect the molecular mechanisms underlying the pleiotropic impact of GWAS on T2D associated genes. Modulating *Cdkn2a*-regulated signaling cascades may constitute novel targetable pathways for treating metabolic disorders.
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The following are the supplementary data related to this article:Figure S1(A, B) A 16 h fasting blood glucose levels in *Cdkn2a+/+* and *Cdkn2a−/−* chow (A) and HFD (B) fed mice (*n* = 4). Related to [Figure 1](#fig1){ref-type="fig"}.Figure S2(A, B) Cumulative food intake of control (*Cdkn2a+/+*) and mutant (*Cdkn2a−/−*) mice under CD (A) and HFD (B) was measured during 3 consecutive days (*n* = 4). (C--F) 3 days measurement of ambulatory activity (C, E) and its quantification (D, F) of *Cdkn2a+/+* and *Cdkn2a−/−* mice placed in metabolic cages fed a CD (C, D) or HFD (E, F) (*n* = 4). (G, H) 3 days measurement of heat output for *Cdkn2a+/+* and *Cdkn2a−/−* under CD (g) and HFD (h) fed mice (*n* = 4). (I, J) Respiratory exchange ratio (RER) was evaluated during 3 days in *Cdkn2a+/+* and *Cdkn2a−/−* fed a chow (I) and HFD (J) diet (*n* = 4). All values are expressed as means ± SEM. Related to [Figure 2](#fig2){ref-type="fig"}.Figure S3(A) Mitochondrial DNA content (mtDNA) measured relative to nuclear DNA in BAT and in ingWAT tissues of *Cdkn2a+/+* and *Cdkn2a−/−* mice (*n* = 6--10). (B, C) Western blot assays showing UCP1 levels (B) and its quantification (C) in BAT tissues of *Cdkn2a+/+* and *Cdkn2a−/−* mice (*n* = 3). (D, E) Absolute BAT weight under chow (D) or HFD (E). (F, G) Relative BAT weight to total body weight under chow (D) or HFD (E). (H) Representative immunofluorescence images of inguinal WAT sections showing nuclei labeling (Hoechst, blue), IgG (negative control) and UCP1 staining (green) on *Cdkn2a+/+* and *Cdkn2a−/−* mice. All values are expressed as means ± SEM. Related to [Figure 3](#fig3){ref-type="fig"}.Figure S4(A) Strategy and subsequent experiments used to analyze the effect of *Cdkn2a* on browning. (B) Bodipy staining of differentiated ingWAT, eWAT and BAT adipocytes from *Cdkn2a+/+* and *Cdkn2a−/−* mice. (C) mRNA levels for adipogenic and thermogenic genes in BAT primary adipocytes isolated from *Cdkn2a+/+* and C*dkn2a−/−* mice after 8 days induction of differentiation (*n* = 3). (D, E) Western blot assays (D) and their quantification (E) showing PKA substrates in *Cdkn2a+/+* and *Cdkn2a−/−* ingWAT tissue homogenates. Tubulin was used as loading controls. All values are expressed as means ± SEM. \**p* \< 0.05, \*\**p* \< 0.01 and \*\*\**p* \< 0.001. Related to [Figure 4](#fig4){ref-type="fig"}.Figure S5(A) IPA analysis showing gene network associated to *Cdkn2a* deletion involved in "energy production, lipid metabolism and small molecule biochemistry". Related to [Results](#sec3){ref-type="sec"} section.Table S1List of peptides differentially phosphorylated in *Cdkn2a+/+* and *Cdkn2a−/−* primary adipocytes. Related to [Figure 4](#fig4){ref-type="fig"}.Table S2Pathway analysis of diseases and/or biological functions affected in *Cdkn2a+/+* and *Cdkn2a−/−* primary adipocytes related to differential peptide phosphorylation. Related to [Figure 4](#fig4){ref-type="fig"}.Table S3List of transcripts differentially regulated in *Cdkn2a+/+* and *Cdkn2a−/−* primary adipocytes identified by RNA-sequencing (download at <https://drop-good.egid.fr/index.php/s/Pu8IB6dYCFR1N6T>). Related to [Results](#sec3){ref-type="sec"} section.Table S4List of diseases and/or biological functions associated to gene expression profiling of *Cdkn2a+/+* and *Cdkn2a−/−* primary adipocytes. Related to [Results](#sec3){ref-type="sec"} section.Table S5Oligonucleotides sequences used in this study.
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